Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Conventional cohort Clear all
Completed Phase 1 Interventional

Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractory to Conventional Therapy

NCT05990920
View directory record Official record
Conditions
Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer, Metastatic Cancer, Recurrent Cancer, Solid Tumor, Adult, Solid Tumor, Advanced Cancer, Advanced Solid Tumor
Interventions
SNK02
Biological
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 25, 2026, 10:56 PM EDT
Recruiting Phase 4 Interventional

Dual Mobility Acetabular Cups in Revision TJA

NCT04090359
View directory record Official record
Conditions
Dislocation, Hip
Interventions
Dual Mobility Implant, Conventional, single-bearing implant
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2036
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 25, 2026, 10:56 PM EDT
Active, not recruiting Phase 2 Interventional

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

NCT03784326
View directory record Official record
Conditions
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Atezolizumab, Conventional Surgery, Fluorouracil, Oxaliplatin, Tiragolumab
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 25, 2026, 10:56 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Itacitinib + Everolimus in Hodgkin Lymphoma

NCT03697408
View directory record Official record
Conditions
Classical Hodgkin Lymphoma
Interventions
Itacitinib, Everolimus
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 25, 2026, 10:56 PM EDT
Recruiting Not applicable Interventional

Biologically-Adapted, Dose-Escalated Radiotherapy for the Treatment of Ewing Sarcoma, BEAR Trial

NCT07188532
View directory record Official record
Conditions
Ewing Sarcoma, Round Cell Sarcoma With EWSR1-non-ETS Fusion
Interventions
Biospecimen Collection, Chemotherapy, Computed Tomography, Conventional Radiotherapy, Definitive Surgical Resection, Dose-escalated Radiation Therapy, Electronic Health Record Review, External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Phoenix, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 25, 2026, 10:56 PM EDT
Active, not recruiting Phase 2 Interventional

Genetic Testing in Predicting Tumor Response in Patients With Stage I-III HER2 Negative Invasive Breast Cancer

NCT01334021
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Biopsy, Conventional Surgery, Genetic Testing
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 10:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Low Dose CT for Total Shoulder Arthroplasty/Reverse Shoulder Arthroplasty

NCT05350319
View directory record Official record
Conditions
Shoulder Arthroplasty
Interventions
A low-dose CT scan of the shoulder
Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer

NCT03211117
View directory record Official record
Conditions
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma
Interventions
Docetaxel, Doxorubicin Hydrochloride, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Therapeutic Conventional Surgery
Drug · Radiation · Other + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Results available

Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

NCT04318080
View directory record Official record
Conditions
Classical Hodgkin Lymphoma
Interventions
Tislelizumab
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Detroit, Michigan • Knoxville, Tennessee • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Results available

Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia

NCT03257462
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, CAH - Congenital Adrenal Hyperplasia
Interventions
SPR001
Drug
Lead sponsor
Spruce Biosciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Orange, California • San Diego, California • Melbourne, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 1 Interventional

Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer

NCT00052559
View directory record Official record
Conditions
Adenocarcinoma of the Rectum, Stage II Rectal Cancer, Stage III Rectal Cancer
Interventions
bevacizumab, fluorouracil, external beam radiation therapy, therapeutic conventional surgery, laboratory biomarker analysis
Biological · Drug · Radiation + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 25, 2026, 10:56 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

3-D Super Resolution Ultrasound Microvascular Imaging

NCT04136912
View directory record Official record
Conditions
Breast Cancer, Thyroid Cancer
Interventions
Definity, Acoustic Angiography
Drug · Device
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Not applicable Interventional

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

NCT01868451
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab vedotin (SGN-35), Doxorubicin HCL, Vinblastine Sulfate, Dacarbazine, Involved-Site Radiation Therapy (ISRT), Interim PET, consolidation volume RT (CVRT)
Drug · Radiation · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
10
States / cities
Duarte, California • Stanford, California • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 25, 2026, 10:56 PM EDT
Recruiting Phase 1 Interventional

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT05283330
View directory record Official record
Conditions
Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
Interventions
²¹²Pb-DOTAM-GRPR1
Drug
Lead sponsor
Orano Med Theranostics, SAS
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
8
States / cities
Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 25, 2026, 10:56 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

NCT03592264
View directory record Official record
Conditions
Solid Tumor, Pancreatic Adenocarcinoma
Interventions
OBI-3424
Drug
Lead sponsor
OBI Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • New Brunswick, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 25, 2026, 10:56 PM EDT
Terminated Phase 2 Interventional Results available

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

NCT03267680
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion
Interventions
Cyclophosphamide, Indomethacin, IRX-2, Laboratory Biomarker Analysis, Multivitamin, Omeprazole, Placebo, Therapeutic Conventional Surgery
Drug · Biological · Other + 2 more
Lead sponsor
University of Southern California
Other
Eligibility
25 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Sep 25, 2026, 10:56 PM EDT
Active, not recruiting No phase listed Observational

Ultra High Resolution CT to Assess Role of Intramyocardial Fat and Delayed Enhancement in Ventricular Arrhythmogenesis

NCT04394637
View directory record Official record
Conditions
Ventricular Arrhythmias
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Pediatric Safety and Immunogenicity Study of Cell-Culture Derived and Egg-based Subunit Influenza Vaccines in Healthy Children and Adolescents

NCT00645411
View directory record Official record
Conditions
Influenza
Interventions
Cell culture-derived influenza subunit vaccine (cTIV), Egg derived influenza subunit vaccine (eTIV)
Biological
Lead sponsor
Novartis
Industry
Eligibility
3 Years to 17 Years
Enrollment
3,604 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
16
States / cities
Fayetteville, Arkansas • Downey, California • Bardstown, Kentucky + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2015 · Synced Sep 25, 2026, 10:56 PM EDT
Terminated Phase 2 Interventional Results available

Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia

NCT00503581
View directory record Official record
Conditions
High Grade Squamous Intraepithelial Neoplasia, Stage 0 Uterine Corpus Cancer
Interventions
Biopsy, Laboratory Biomarker Analysis, Megestrol Acetate, Pharmacological Study, Quality-of-Life Assessment, Therapeutic Conventional Surgery
Procedure · Other · Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
50
States / cities
Los Angeles, California • Sylmar, California • Hartford, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 2 Interventional Results available

Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer

NCT00881361
View directory record Official record
Conditions
Breast Cancer
Interventions
systemic chemotherapy, axillary lymph node dissection, neoadjuvant therapy, sentinel lymph node biopsy, therapeutic conventional surgery, ultrasound imaging
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
324
States / cities
Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 232 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Results available

Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST

NCT02164240
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
Sunitinib, Regorafenib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 25, 2026, 10:56 PM EDT
Completed Phase 1 Interventional Results available

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

NCT03107988
View directory record Official record
Conditions
Neuroblastoma
Interventions
Lorlatinib, Cyclophosphamide, Topotecan, Filgrastim/pegfilgrastim
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 99 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 25, 2026, 10:56 PM EDT
Active, not recruiting Phase 1 Interventional

Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

NCT02015117
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Conventional Surgery, Trametinib, Whole-Brain Radiotherapy
Other · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 25, 2026, 10:56 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

NCT03406611
View directory record Official record
Conditions
Homocystinuria
Interventions
Pegtibatinase, Placebo
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
5 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 25, 2026, 10:56 PM EDT